Thelansis

Endometriosis Emerging Therapy and TPP Insights Thelansis’s “Endometriosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Endometriosis Overview Endometriosis is a chronic, estrogen-dependent, and highly debilitating systemic inflammatory disease defined by the ectopic proliferation of endometrial-like tissue (glands and stroma) outside the uterine cavity. Most frequently localizing to the pelvic peritoneum, ovaries, and uterosacral ligaments, the disease is clinically classified into three distinct anatomic phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can aggressively invade the bowel and bladder. Far from a benign condition, these ectopic lesions undergo cyc...

Endometriosis Emerging Therapy and TPP Insights Thelansis’s “Endometriosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and ...

Endometriosis Market Outlook Thelansis’s “Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do inter...

Endometriosis Market Outlook Thelansis’s “Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Endometriosis Overview Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladder regions. While occasion...

  Hope Medicine Inc., a clinical-stage innovative biopharmaceutical company, announced positive results from an interim analysis of a global Phase 2 study, titled “A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis Associated Pain Over a 12-Week Treatment Period.” HMI-115 is a monoclonal antibody that blocks the prolactin receptor and serves as a first-in-class treatment for endometriosis. Publish Date: 24-10-2024   Source: Hope Medicine Inc. Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladde...

 Endometriosis, a condition characterized by the abnormal proliferation of endometrial tissue similar to that lining the uterus but occurring outside it, manifests as endometrial implants in ectopic sites. These lesions are commonly found on organs such as the ovaries, Fallopian tubes, uterine surface, bowel, and pelvic cavity membrane (peritoneum), with less frequent occurrences in the vaginal, cervical, and bladder regions. While occasionally found outside the pelvis, endometriosis generally remains confined to the pelvic area. Endometrial implants can lead to complications, but they typically pose no significant harm. The severity of endometriosis is classified into four stages—mild (Stage I), mild (Stage II), moderate (Stage III), and severe (Stage IV)—based on criteria including the number, location, and depth of implants and the presence of filmy or dense adhesions. Another staging system primarily assesses the severity of pelvic pain. However, a more reliable staging method ...

  Endometriosis is defined as the abnormal growth of endometrial tissue, which is similar to that which lines the interior of the uterus but occurs outside of the uterus. During menstruation, endometrial tissue is shed. Endometrial implants are areas of endometrial tissue found in ectopic sites. These lesions are most generally found on the ovaries, the Fallopian Tubes, the uterine surface, the bowel, and the pelvic cavity membrane lining (i.e., the peritoneum). They are less frequently found in the vaginal, cervix, and bladder. Endometriosis can occur outside the pelvis on rare occasions. While endometrial implants can cause complications, they are usually harmless. Endometriosis is classified into four stages: I (mild), II (mild), III (moderate), and IV (severe) based on the number, location, and depth of implants, as well as the presence of filmy or dense adhesions. Another staging system is based primarily on the company and severity of pelvic pain. However, a more reliable sta...

  Endometriosis is defined as the abnormal growth of endometrial tissue, which is similar to that which lines the interior of the uterus but occurs outside of the uterus. During menstruation, endometrial tissue is shed. Endometrial implants are areas of endometrial tissue found in ectopic sites. These lesions are most generally found on the ovaries, the Fallopian Tubes, the uterine surface, the bowel, and the pelvic cavity membrane lining (i.e., the peritoneum). They are less frequently found in the vaginal, cervix, and bladder. Endometriosis can occur outside the pelvis on rare occasions. While endometrial implants can cause complications, they are usually harmless. Endometriosis is classified into four stages: I (mild), II (mild), III (moderate), and IV (severe) based on the number, location, and depth of implants, as well as the presence of filmy or dense adhesions. Another staging system is based primarily on the company and severity of pelvic pain. However, a more reliable sta...